RI
MLYS icon

RTW Investments’s Mineralys Therapeutics MLYS Stock Holding History

RTW Investments’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-922,100
Closed -$8.77M – 69
2023
Q3 		$8.77M Hold
922,100
– – 0.19% 50
2023
Q2 		$15.7M Hold
922,100
– – 0.3% 44
2023
Q1 		$14.4M Buy
+922,100
New +$15.5M 0.3% 38

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RTW Investments's MLYS Position: Q4 2023 in Review

RTW Investments sold out of Mineralys Therapeutics (MLYS) in Q4 2023, closing a stake of 922,100 shares — an estimated $8.77M sold.

RTW Investments first reported a position in MLYS in Q1 2023 and held it in 3 quarters. The position peaked at $15.7M in Q2 2023. 87 funds tracked by Wall St. Rank hold MLYS as of Q4 2023.

  • RTW Investments reported no remaining Mineralys Therapeutics position as of Q4 2023 after selling out during the quarter.
  • RTW Investments sold 922,100 Mineralys Therapeutics shares in Q4 2023, an estimated $8.77M.
  • RTW Investments first reported a position in Mineralys Therapeutics in Q1 2023 and held it in 3 quarters.
  • RTW Investments's Mineralys Therapeutics position peaked at $15.7M in Q2 2023.
  • 87 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q4 2023.

Based on RTW Investments's 13F filing for Q4 2023, filed 14 Feb 2024.